Somewhat Favorable News Coverage Somewhat Unlikely to Impact Sucampo Pharmaceuticals (SCMP) Share Price
Media coverage about Sucampo Pharmaceuticals (NASDAQ:SCMP) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.4666297589232 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several equities research analysts recently commented on the company. Maxim Group reissued a “buy” rating and set a $23.00 target price on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. Mizuho cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $14.00 to $12.00 in a report on Tuesday, October 3rd. BidaskClub cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. TheStreet cut shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Finally, B. Riley began coverage on shares of Sucampo Pharmaceuticals in a report on Tuesday, November 14th. They issued a “buy” rating and a $14.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Sucampo Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $16.00.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $10.55 on Friday. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.55. The stock has a market cap of $478.03, a PE ratio of 7.09, a price-to-earnings-growth ratio of 3.11 and a beta of 1.38.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. During the same period in the prior year, the company earned $0.30 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. equities research analysts predict that Sucampo Pharmaceuticals will post 1.11 EPS for the current fiscal year.
In other news, insider Jason Patrick Meyenburg purchased 4,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was bought at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the completion of the acquisition, the insider now directly owns 30,228 shares of the company’s stock, valued at $366,665.64. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Sucampo Pharmaceuticals (SCMP) Share Price” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://theolympiareport.com/2017/11/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-sucampo-pharmaceuticals-scmp-share-price.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.